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John Sulston, who coordinated 
the UK side of the international 
publicly funded efforts to sequence 
‘the’ human genome, once said the 
endeavour was like a moon shot. He 
may only have referred to the scale 
and ambition of the project, but one 
could argue that, in both cases, 
outdated technology and extraordinary 
amounts of money were used to hit a 
highly visible and prestigious target, 
just to show that one can do it. In both 
cases, the benefits remained rather 
limited. While the moon landings 
turned into a picturesque blind alley 
of human exploration, the really useful 
work in human genomics only started 
after the first human genome was 
mostly complete. 
Like the moon landings, the human 
genome project used technology 
that had essentially been available 
for decades. In this case, it was the 
chain termination sequencing method, 
which Frederick Sanger developed 
around 1975, and which earned him 
his second Nobel Prize in 1980. It was 
made more efficient later when the 
read-out of radioactive labels from a 
slab gel was replaced by fluorescence 
marking (with different colours 
indicating As, Cs, Gs and Ts) and 
capillary electrophoresis. 
Sanger’s principle, however, 
remained in place, and its Achilles’ heel 
is the fact that every single position 
of the sequence to be read has to be 
represented by a population of DNA 
molecules that ends with this position. 
Hence, the amount of DNA required is 
much larger than the minimal number 
of molecules that can be detected by 
the read-out technique. The theoretical 
minimum is the detection limit times 
half the length of the sequence to be 
determined in one run (which is the 
average length of the fragments if 
you have equal numbers of fragments 
ending at each position). 
This principle, while tolerable in small 
sequencing projects, is what made the 
human genome project astronomically 
expensive. If sequencing genomes 
were ever to become useful, one had 
to get out of the chain termination 
principle. And ideally one would also 
want to achieve what cells have been 
doing for billions of years, namely read 
individual DNA molecules rather than 
populations of thousands. 
The second generation
As the human genome juggernaut 
approached the final stages of the 
project, only slightly spurred on by 
the competition from Craig Venter’s 
private effort, which also relied on 
Sanger sequencing, researchers 
were already thinking about the next 
generation that would not terminate 
and discard a population of DNA 
chains for every base read. 
In 2005, just two years after the 
official completion of the human 
genome project, the first of the ‘next 
generation’ sequencing machines 
reached the market. Within two years, 
several companies introduced new 
techniques, all of which managed to 
avoid the fundamental problem with 
chain termination in different ways. 
The current market leader, Illumina, 
uses the Solexa technique, which is 
based on fluorescent labels and chain 
termination, just like its predecessors. 
The clever trick, however, is that a 
chemical modification to the  
chain-terminating nucleotides makes 
the termination reversible. After the 
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Singular genome: Stephen Quake was the first person to have his genome sequenced by 
single-molecule technology. (Photo: Cambridge Healthtech Media Group, Bio-IT World.)
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base has been identified, the block 
can be removed, and the next base 
can be attached. 
In the pyrophosphate technique in 
the instruments from the company 454, 
which have sequenced the genomes 
of James Watson and a nameless 
Neanderthal, the pyrophosphate 
cleaved off during the chain elongation 
reaction provides a signal that a 
nucleotide has been attached, so there 
is no chain termination involved. 
Applied Biosystems, a market leader 
in the times of Sanger sequencing, 
uses the SOLiD technology, which 
constructs a complementary strand 
from short labelled oligonucleotides. 
Between them, these ‘next 
generation’ techniques have 
succeeded in driving down the cost 
of a human genome by five orders 
of magnitude, from around a billion 
dollars to tens of thousands of dollars, 
and have enabled the advent of 
personal genomics, i.e. the sequencing 
of many individual human genomes. 
Major sequencing centres like the 
Wellcome Trust Sanger Centre at 
Hinxton near Cambridge and the BGI 
at Shenzhen, China, have more than 
100 second generation instruments, 
enabling them to read the equivalent 
of dozens of human genomes per 
day. However, there is still room for 
improvement both in the amount of 
DNA needed for a sequencing run, 
and in the bulk of equipment required 
for the process. 
The third generation 
When the cell transcribes and translates 
genetic information, it always starts 
from a single molecule of DNA, which 
is read out by molecular machines at 
breathtaking speed. So why can’t we 
build machines that achieve the same? 
Recent years have seen increasing 
efforts to bring down read-out 
sensitivity to the single-molecule level. 
The first commercial instrument to 
achieve this is the heliscope produced 
by the company Helicos Biosciences. 
In 2009, Helicos co-founder Stephen 
Quake published the sequence of his 
own genome, the first human genome 
to be analysed by single-molecule 
techniques. Last year, Quake went 
one step further and published a full 
medical analysis of the information 
extracted from his genome (The 
Lancet (2010), 375, 1525–1535). 
Like the now ubiquitous Solexa 
technique, the Helicos instrument 
monitors the synthesis of new DNA 
using fluorescence detection. The DNA 
strands are anchored on a microchip 
and offered nucleotides for chain 
extension one sort at a time. After each 
reaction, the machine takes a photo of 
the chip, with a bright spot identifying 
each chain that has had a successful 
chain extension reaction with the 
nucleotide that has been offered. 
This method won the race to be 
the first single-molecule sequencer 
on the market, and the sequencing 
of Quake’s genome with minimal 
manpower and consumables cost 
clearly demonstrated its usefulness. 
Its weakness, however, is the optical 
detection of the chain extension, 
which depends on the precise 
location of each DNA strand in the 
microphotograph. This requires a 
vibration-free set-up, i.e. a large granite 
table in a suitable building. It makes 
the instrument significantly more 
expensive than the ones currently in 
use, and rules out any thoughts of 
widespread use in medical practices. 
Last December, Life Technologies — 
the company resulting from the merger 
of Applied Biosystems and Invitrogen — 
at Carlsbad, California, launched the Ion 
Personal Genomics Machine developed 
by the start-up company Ion Torrent, 
which Life Technologies had bought 
up just months earlier. Ion Torrent is the 
brainchild of Jonathan Rothberg, who 
also developed the 454 technology. 
While it doesn’t achieve single-
molecule resolution, the Ion Torrent 
technology has an advantage that 
Counting protons: The Ion Personal Genomics Machine from Life Technologies uses the 
hydrogen ions released during nucleotide coupling as an indicator of DNA extension. (Photo: 
© Life Technologies.)
the Helicos approach lacks in that it 
uses electronic detection. It is based 
on a novel approach, namely the 
detection of hydrogen ions released 
during the nucleotide coupling. 
Thus, the machine is essentially a 
highly sophisticated pH meter. In 
each reaction step, one of the four 
nucleotides is offered for chain 
extension, and from the amplitude of 
the signal produced by the protons 
released, one can conclude whether 
one or several copies of the specific 
nucleotide were appended to the 
growing chain. As electronic detection 
is much simpler than optical methods, 
the resulting instrument is a user-
friendly and relatively affordable 
desktop box that could be installed 
anywhere. 
The company Pacific Biosciences 
(PacBio) at Menlo Park, California 
announced at the end of April 
that, following a limited trial phase 
with selected institutions, it is now 
shipping its new sequencer on a full-
scale commercial base. A prototype 
has already served in identifying the 
origin of the cholera germs during the 
recent outbreak in Haiti (N. Engl. J. 
Med. (2011), 364, 33–42). 
The Wellcome Trust Sanger Centre 
already has one PacBio RS alongside 
two Ion Torrent machines, with the 
aim to explore the new technologies. 
A spokesman said: “Although they will 
initially be used as a research platform, 
our experience with these devices 
will give us insight into the direction 
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Smart sequencing: Production of the PacBio RS at Pacific Biosciences, Menlo Park, which 
uses single-molecule technology with fluorescence detection. (Photo: © Pacific Biosciences.)
that DNA sequencing technology will 
go and allow us to develop plans to 
support and exploit it.”
PacBio uses synthesis-based 
sequencing and fluorescence 
detection like most of the existing 
instruments, but has managed to scale 
down the reaction vessel to the extent 
that only one DNA molecule can fit in. 
The key component is a trough 
measuring only tens of nanometres 
across. As this is much below the 
wavelength of visible light, the trough 
acts as a zero mode waveguide (ZMW), 
allowing light only to penetrate some 
20–30 nanometres into the space, which 
means that the volume accessible to 
the light is as small as 20 zeptolitres 
(10–21 litres). On a larger scale, the same 
phenomenon is used in the perforated 
screens in the doors of microwave 
ovens. As microwaves have much 
longer wavelengths than visible light, 
the holes that are impenetrable to them 
are transparent for visible light.  
If a DNA polymerase operates within 
this very small volume, replicating a 
single DNA strand, there is no space for 
other molecules that might contribute 
any noise. Thus, any fluorescence signal 
coming back from this cavity is bound 
to be a relevant signal indicating the 
extension of the chain with a nucleotide. 
To be quite sure that there is no 
unwanted fluorescence, PacBio have 
attached the fluorescence label to the 
pyrophosphate that is cleaved off during 
the coupling reaction, meaning that the 
growing chain doesn’t fluoresce. 
Another company that has been 
developing new technologies in recent 
years is Complete Genomics, based 
in Mountain View, California. However, 
this company does not aim to sell 
instruments. Instead it only builds them 
for its own use in commercial DNA 
sequencing. Thus, the company doesn’t 
divulge too much information about 
their technology. Their key innovation 
appears to be in the way of immobilising 
DNA strands using ‘DNA nanoballs’. 
The materials cost quoted by Complete 
Genomics for a personal genome has 
been comparable if not lower than 
that obtained with other instruments, 
suggesting that the technology is on the 
same level as those of the companies 
developing commercial instruments.  
Towards the perfect genome 
sequencer
So far, each of the new instruments 
has fulfilled some but not all of the 
hopes attached to the coming of the 
third generation. The Heliscope and 
Pacific Biosciences RS have achieved 
single-molecule sequencing, and Ion 
Torrent has electronic detection. But 
can these improvements be achieved 
in the same instrument, and can this 
instrument be compact, affordable, 
and user-friendly? 
Up to now, it is far from clear which 
of the competing companies may win 
the race to the perfect third generation 
machine, the one that may turn up on 
the desk of your family doctor at some 
point in the future. 
Oxford Nanopore Technologies is 
aiming for no less than the complete 
package: single-molecule, electronic, 
compact, scalable, affordable, and 
user-friendly. Originally spun out of 
the laboratory of Hagan Bayley at the 
University of Oxford, Oxford Nanopore 
now has collaborations with Harvard, 
the University of California at Santa 
Clara (UCSC) and other institutions.
Oxford Nanopore is exploring two 
methods of DNA sequencing with 
biological nanopores: exonuclease 
sequencing (for which the company 
has a commercialisation agreement 
with Illumina) and strand sequencing.  
A team at the company led by Chief 
Scientific Officer John Milton, who 
also developed the Solexa technique, 
has made adaptations to biological 
nanopores so that they can be used 
to identify DNA bases in sequence. 
Nanopore sequencing uses a potential 
difference across the membrane to 
drive DNA through the pore as individual 
nucleotides or an intact strand. 
A previous publication from Oxford 
Nanopore has shown individual 
identification of each of the four DNA 
nucleotides, as each affects the current 
across the membrane in a characteristic 
way. In addition, the set-up can also 
identify the methylated cytosine, 
which is important for epigenetic 
research. In both the exonuclease and 
strand methods a processive enzyme 
manipulates the DNA to pass it through 
the nanopore; recent research in this 
area includes that of Mark Akeson’s 
UCSC laboratory which showed that 
the enzyme phi29 can ratchet single-
stranded DNA through a nanopore. 
Apart from this work with biological 
nanopores, Oxford Nanopore also has 
an interest in solid-state nanopores and 
has recently signed a licence agreement 
with Harvard University covering the 
development of graphene nanopores.
Another intriguing approach has 
been explored by the company VisiGen 
Biotechnologies, which is now also 
part of Life Technologies. VisiGen 
researchers have coupled the DNA 
polymerase with a quantum dot, whose 
optical properties are so sensitive to 
the molecular environment that it can 
distinguish which of the four nucleotides 
has just docked to the polymerase. 
However, it is not clear yet whether 
the technique can distinguish between 
productive encounters that lead to chain 
extension and non-productive ones, 
in which a non-matching nucleotide is 
checked and then discarded. 
Magazine
R297
Pore progress: Oxford Nanopore’s modified 
nanopore can distinguish between the four 
standard DNA nucleotides and methylated 
cytosine. The aim is to use an endonuclease 
(green) to feed the nucleotides to the pore 
one by one. (Photo: iemedia solutions.)
Coming soon to a doctor’s surgery 
near you?
Hopes placed on the sequencing 
of ‘the’ human genome and the 
subsequent identification of many 
single-nucleotide polymorphisms 
(SNPs) have turned out to be 
misguided, as the causes of common 
diseases like cancer and heart disease 
have proven too complex to be 
addressed with simple SNP searches. 
Also, large-scale genomic differences 
like copy number variations (CNV) 
and insertions/deletions (indels) are 
now known to be equally important as 
SNPs, rendering the quest for genomic 
answers to medical problems ever 
more challenging. 
There is, however, the hope that 
large-scale analysis of individual 
genomes may yield some of the 
answers that SNPs failed to provide. 
And the rapid progress in sequencing 
technology, with the costs dropping 
more rapidly than those of computer 
technology (still following Moore’s 
Law), means that comparing 
thousands of individual genomes, 
thoughtfully chosen by epidemiological 
criteria, is now a perfectly viable 
approach to medical genomics.
At the more individual level, 
affordable genome analysis is also 
bound to aid diagnosis and therapy, 
especially in cancer. Soon it will be 
easy to compare the genome of a 
tumour with that of the patient’s 
healthy cells, enabling doctors to find 
out both what went wrong and what 
treatment is most likely to succeed. 
And this, when it happens, will be the 
real genome revolution.
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
page at www.michaelgross.co.uk
But isn’t NETosis just apoptosis 
by another name? Actually, no! 
These two processes are mediated 
by different pathways, with NETosis 
involving a distinct set of events. 
The primary difference between 
these two cell-death routines is the 
dramatic change that occurs in the 
nucleus of neutrophils committed 
to NET formation. The hallmark of 
the process is nuclear envelope 
breakdown, followed by expansion 
and decondensation of the chromatin. 
This is accompanied by release 
of anti-microbial proteins from 
neutrophil granules; these proteins 
subsequently mix with and adhere to 
the decondensed chromatin. The  
process culminates in rupture of the 
plasma membrane and, finally, release 
of a NET. In contrast, apoptosis 
involves DNA fragmentation and 
nuclear shrinkage, without breakdown 
of membranes. Similarly, in another 
cell-death process, necrosis, DNA 
remains enclosed in a nuclear 
envelope, although the typical 
lobulation of the neutrophil nucleus 
is lost. Despite similarities with these 
other pathways, NETosis is clearly a 
distinct process from other cell-death 
mechanisms.
How are NETs formed? The 
molecular details of NET formation 
have only recently begun to be 
unravelled. The phenomenon is 
tightly linked to the production 
of reactive oxygen species (ROS) 
by neutrophil NADPH oxidase. 
Accordingly, patients with mutations 
in this enzyme fail to make NETs and 
suffer from debilitating infections. 
In addition, individuals lacking 
myeloperoxidase, another key 
enzyme in the ROS cascade,  
are also unable to make NETs, thus 
providing further evidence for a role 
for ROS in NET formation. Although 
important, ROS are not the only 
crucial players in NET formation. 
During NETosis, decondensation  
of chromatin is also critical for 
proper NET formation. Recently, a 
role for neutrophil elastase  
in the decondensation process  
was demonstrated; this serine 
protease was shown to partially 
degrade histones. Histone  
cleavage presumably leads to 
relaxation and decondensation  
of chromatin and is thus a  
pivotal event in the process of  
NET formation.
Neutrophil 
extracellular traps 
Borko Amulic and Garret Hayes
What are neutrophil extracellular 
traps, or NETs? Neutrophils, the most 
abundant immune cells in humans, 
are the first line of defense against 
invading pathogens. They employ a 
wide array of anti-microbial strategies, 
most notably phagocytosis, to attack 
and eliminate pathogens. In 2004 a 
new and unexpected anti-microbial 
activity of neutrophils was uncovered: 
upon encountering bacteria, 
neutrophils release a mesh-like 
structure capable of ensnaring and 
eliminating microbes (Figure 1). These 
web-like traps contain a backbone 
consisting of DNA/histones and are 
peppered with anti-microbial peptides 
that normally reside within the 
neutrophil granules. These structures 
were dubbed NETs and the process of 
NET formation is known as NETosis.
What is the role of NETs 
in immunity? NETosis is an 
anti-microbial strategy that results in 
neutrophil death and contributes to 
pathogen control and elimination.  
In vitro, the microbicidal properties of 
NETs have been clearly demonstrated: 
they trap pathogens and prevent them 
from dispersing, while simultaneously 
destroying them through  
exposure to a high concentration of 
anti-microbial effectors. These  
anti-microbial effectors include, as 
expected, the anti-microbial proteins 
of the neutrophil granules. Perhaps 
unexpectedly, the histones in NETs 
are also key components of the anti-
microbial repertoire. It has long been 
known that histones are some of the 
most powerful anti-microbial agents 
that exist. Nevertheless, exactly how 
this anti-microbial activity of histones 
could be effectively harnessed was 
a long-standing and intractable 
mystery. The discovery of NETs 
presents a satisfying explanation 
for this apparent dilemma. Through 
NET formation, neutrophils provide 
histones with an opportunity to 
execute their alternative, non-
structural function: microbial killing.
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